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Background: Reduced glutathione (GSH) is a major antioxidant in the lung. In cystic fibrosis (CF) patients, extracellular GSH levels of
lower airways, obtained by bronchoalveolar lavage (BAL), were reported to be lower than non-CF individuals. Methods: Upper airway
secretions of stable adult CF patients (29 spontaneous and 13 induced sputum) and non-CF individuals (14 healthy and 12 asthmatics; all
induced sputum) were analyzed for total glutathione (i.e. the sum of reduced, GSH, and oxidized, GSSG, forms), GSH and GSSG levels by
enzymatic kinetic assay. Results: In CF, both spontaneous and induced sputum samples were comparable in total glutathione levels which
were surprisingly high (median concentration of 9.2 (range 1.4–65.2) and 11.6 (1.1–69.8) AM, respectively). In non-CF individuals, total
glutathione levels were significantly lower (healthy 2.8 (1.0–12.3), asthmatics (5.3 (1.3–19.2) AM; p < 0.001, both vs. CF). In CF, more than
90% of total glutathione was represented by GSH, whereas in non-CF controls, GSH made up less than 50% of total glutathione ( p < 0.001).
Conclusions: In contrast to BAL, CF sputum contains high levels of GSH. Sputum induction is a potentially useful procedure to monitor
antioxidant levels in upper airways of CF patients.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Lung inflammatory diseases; Antioxidant levels; Upper airway secretions1. Introduction
Cystic fibrosis (CF) is the most common lethal hereditary
disease in Caucasian population. The clinical picture and
outcome in adult CF patients are determined by the CF lung
disease which is characterized by chronic bacterial infection
and chronic extensive inflammation in airways [1]. In CF,
gene mutations result in defective, malfunctioning or absent
CF transmembrane conductance regulator (CFTR) protein
that in a normal cell functions as a cAMP-regulated chloride
channel. However, it is not clear how the abnormalities in
CFTR channel function cause the clinical disease. There are
recent reports indicating that dysfunctioning of CFTR1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.03.005
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E-mail address: bargon@em.uni-frankfurt.de (J. Bargon).channel may affect antioxidant defence in the lung. In
particular, it was demonstrated than normally, the transport
of reduced glutathione (GSH, the principal antioxidant in
the lung [2,3]) out of the cell is chloride-dependent and
involves CFTR channel [4–6]. Airway epithelial lining
fluid (ELF) of healthy individuals contains high concen-
trations of GSH [7] which are more than 100-fold higher
than those of blood plasma. In addition, normal airway ELF
also contains other components of GSH redox cycle such as
glutathione peroxidase and reductase [7]. In CF, both ELF
and blood plasma exhibit GSH levels lower than in healthy
[8].
Given the potential importance of GSH in pathogenesis
of CF lung disease, it might be interesting to monitor airway
GSH in CF. Currently, there is no routine tool to perform
such monitoring in CF. Bronchoalveolar lavage (BAL) used
in previous studies in CF [8,9] is not practical for longitu-
dinal observations due to the labour-intensive character,
extensive burden on patients and high costs. Recently, the
authors have shown that sampling of airway secretions by
induced sputum can also be used to measure airway GSHed by Elsevier B.V. All rights reserved.
N. Dauletbaev et al. / Journal of Cystic Fibrosis 3 (2004) 119–124120content in healthy and asthmatic individuals [10]. Further-
more, pilot studies in CF [11,12] have demonstrated that
spontaneous sputum is a useful sample for GSH measure-
ment. Although the majority of adult CF patients can easily
produce spontaneous sputum ‘‘on spot’’, younger patients
with milder disease may experience problems expectorating
secretions after the early morning physiotherapy is complet-
ed. Also, sputum induction has become a standard proce-
dure to obtain airway secretions in non-CF individuals. The
present study was designed to address the following ques-
tions: (1) whether airway GSH in CF can be measured in
both spontaneous and induced sputum and (2) whether these
levels would be different from those of non-CF individuals.
In addition, the authors hypothesised that sputum, similar to
BAL, would contain other components of GSH redox
system, such as glutathione peroxidase, and determined
these in CF sputum samples. Since the study addressed
primarily methodological issues, it was designed as a cross-
sectional study which allows to obtain quick and reliable
results.2. Methods
2.1. Study individuals
Spontaneous and induced sputum samples were obtained
from 42 clinically stable adult CF patients (Table 1). Thirty
four patients had the mutation DF508. CF patients were
recruited from the CF outpatient clinic of Hospital of Johann
Wolfgang Goethe University. In all patients, the diagnosis of
CF was made in early childhood based on the characteristic
clinical picture and was confirmed by repeated sweat tests
and gene mutation screening. CF lung disease of moderate
severity was seen in the majority of patients as assessed by
the degree of disability and repeated pulmonary function
tests (median FEV1 48.9% pred. (range 20.1–119.4); Table
1). Standard CF medications included antibiotics, inhaledTable 1
Demographic and pulmonary function data
Healthy (n= 14) Asthma (n= 12) CF (n= 42)
Age (years) 30
(21–40)
28
(18–40)
29
(19–42)
Gender (M/F) 10/4 10/2 20/22
FVC (L) 5.75
(3.55–6.54)
4.96
(3.39–6.52)
2.92
(1.43–5.1)
FVC (% pred.) 106.0
(83.9–130.8)
95.9
(79.2–130.6)
69.3
(40.3–112.7)*
FEV1 (L) 4.74
(3.13–5.2)
3.84
(2.85–5.22)
1.7
(0.62–4.53)
FEV1 (% pred.) 105.0
(84.7–124.4)
91.4
(64.5–125.5)
48.9
(20.1–119.4)*
CRP (mg/dl) < 0.3 < 0.3 0.65
( < 0.3–5.5)
Data are shown as median (range) values.
*p< 0.001 (Kruskal–Wallis test).bronchodilators/corticosteroids, and substitutional therapy
with vitamins and pancreatic enzymes. Twenty of forty-
two investigated patients (47.6%) were taking 600 mg N-
acetylcysteine daily, all other patients were treated with
ambroxol (60 mg daily).
Non-CF controls were healthy and asthmatic individuals.
Fourteen young healthy individuals were volunteers from
clinical staff of the Hospital and students of Johann Wolf-
gang Goethe University (Table 1). Twelve young clinically
stable individuals with allergic asthma (Table 1) were
recruited from asthma outpatient clinic. The diagnosis of
allergic asthma was made according to standard criteria
[13]. All asthmatics had mild-to-moderate persistent disease
and used inhaled steroids (400–800 Ag budesonide or 500
Ag fluticasone propionate daily) and anti-obstructive (beta-
agonists) medication. None of non-CF controls was on N-
acetylcysteine therapy. All were lifelong nonsmokers and
had no signs of respiratory infection within the last 6 weeks.
The study protocol was approved by the Ethics Commit-
tee of Johann Wolfgang Goethe University.
2.2. Obtaining of sputum samples
Spontaneous sputum samples (CF patients only) were
obtained during pulmonary function tests or chest physio-
therapy. CF patients were asked to rinse their mouths, to
gargle with distilled water and to collect sputum in sterile
plastic tubes. After an appropriate sputum amount (>1 g)
was obtained, the sample tube was stored on ice until further
processing.
Sputum inductions (13 CF patients and all healthy and
asthmatic individuals) were performed according to the
protocol established in our clinic [10]. Subjects inhaled 3%
NaCl for 20 min (ultrasonic nebulizer Ultra-Nebk 2000,
DeVilbiss 99, DeVilbiss Medizinische Produkte, Langen,
Germany). Sputum samples were collected in sterile plastic
tubes chilled on ice. To minimise salivary contamination,
study individuals were instructed to spit saliva and to rinse
their mouths with distilled water before each sputum expec-
toration. Subjects were encouraged to cough up and to
expectorate for at least five times during the induction
procedure.
Obtained sputum samples were visually examined for
blood contamination. Blood contaminated samples were
excluded from further processing.
2.3. Sample processing
2.3.1. Supernatant
In the previous study [10], the authors demonstrated that
dithiothreitol (DTT), the standard sputum homogenizing
agent, significantly interferes with the enzymatic kinetic
assay of glutathione determination. Therefore, DTT was
skipped from the sputum homogenization procedure and
sputum supernatant for GSH analysis was obtained by using
PBS as described below.
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ed from saliva. All plugs from one sample were collected in
a fresh 50-ml tube and sample volume and weight were
registered. Samples were diluted with chilled phosphate-
buffered saline (PBS; all reagents are from Sigma-Aldrich
Chemie, Steinheim, Germany). Per each gram sputum, 3 to
5 ml of PBS was added. Samples were shaken by hand,
vortexed, and gently aspirated in and out of a 25-ml Pasteur
pipet. After centrifugation (300 g, 15 min, 4 jC), sputum
supernatants were gently decanted into a new 50-ml tube
and pelleted sputum plugs were put aside for subsequent cell
processing. Supernatants were filtered through four layers of
sterile cotton gauze and re-centrifuged (800 g, 5 min, 4
jC) to pellet any remaining mucus plugs. Supernatants
collected after the second centrifugation were immediately
assayed for glutathione content.
2.3.2. Cells
Sputum plugs pelleted during the first centrifugation
were diluted with a freshly prepared dispersing solution
(6.5 mM dithiothreitol, 100 mU/ml rhDNase in PBS; 4 ml
per each gram of pellet), vortexed, and incubated for 30 min
at 37 jC with intermittent vortexing. After incubation, the
cell suspension was filtered through two layers of sterile
cotton gauze and centrifuged (300 g, 10 min, 20 jC).
Supernatants were decanted and discarded, cells were
washed with PBS and resuspended in RPMI 1640. Total
and non-squamous cell numbers and non-squamous cell
viability (Trypan blue exclusion) were determined. An
aliquot of the cells containing 30,000 cells was cytospun
(57 g, 10 min, 20 jC; Cytospin 2, Thermo Shandon,
Frankfurt/Main, Germany). Cytospins were stained accord-
ing to the May–Gruenwald–Giemsa protocol and analyzed
for percentage of squamous cells and differential cell counts
of non-squamous cells (i.e. macrophages, neutrophils, lym-
phocytes, eosinophils and ciliated cells). Four hundred non-
squamous cells were counted. Sputum samples were con-
sidered valid if they had a non-squamous cell viability of
more than 60% and a percentage of squamous cells of less
than 60%.
2.4. Evaluation of glutathione levels
The total glutathione (i.e. the sum of reduced, GSH, and
oxidized, GSSG, forms) and GSSG levels were evaluated
using enzymatic kinetic assay [10,14].
To measure total glutathione content, sputum superna-
tants were mixed with an equal volume of 10 mM 5,5V-
dithio-bis-(2-nitrobenzoic acid) (DTNB) in 100 mM potas-
sium phosphate buffer (pH 7.5, 5 mM EDTA). This mixture
was pipetted into a 1-ml plastic cuvette to which then 100
mM potassium phosphate buffer (pH 7.5, 5 mM EDTA),
glutathione reductase and NADPH were added (final con-
centrations of DTNB, glutathione reductase, and NADPH:
0.25 mM, 1 U/ml, and 0.25 AM, respectively). The kinetic
reaction was followed for 2 min at 412 nm (spectropho-tometer DUR-70, Beckman Instruments, Munich, Ger-
many). The total glutathione concentration in samples was
calculated using GSSG standard curve (8–0.25 AM).
To measure GSSG, GSH in the sample was pre-
derivitized with 10 mM N-ethylmaleimide (NEM) in 100
mM potassium phosphate buffer (pH 6.5; 5 mM EDTA)
[16]. Excess NEM was removed by elution of sample
through SEP-PAC C18 column (Waters, Eschborn, Ger-
many) which was pre-equilibrated with methanol and
distilled water. The eluate was added to a 1-ml plastic
cuvette and mixed with 100 mM potassium phosphate
buffer (pH 7.5; 5 mM EDTA), DTNB, glutathione reduc-
tase, and NADPH (final concentrations as above). The
kinetic reaction was followed as described above. GSSG
concentration in samples was calculated using GSSG
standard curve (8–0.25 AM).
GSH levels were expressed as absolute GSH levels
(calculated as difference between the total and oxidized
glutathione levels) and as percent of total glutathione.
In previous studies [10], this procedure did not result in
loss of glutathione. Experiments with known concentrations
of GSH and GSSG added to samples at various steps of
sputum processing demonstrated complete recovery of con-
trols [10].
2.5. Activity of glutathione peroxidase in CF sputum
Twelve spontaneous CF sputum samples were analyzed
for glutathione peroxidase (GPx) activity [15]. CF sputum
supernatants were obtained as described above and frozen
at  80 jC. For GPx activity measurement, samples were
thawed on ice and added to reaction mixture consisting of
buffer (50 mM TRIS–HCl, pH 7.6; 5 mM EDTA), GSH
(final concentration 1 mM), NADPH (0.25 mM), and
glutathione reductase (1 U/ml). Reaction was started by
adding t-butyl hydroperoxide (0.2 mM) or distilled water
(to control for nonspecific oxidation of NADPH). Oxida-
tion of NADPH was followed for 3 min at 340 nm.
Activity of GPx was calculated from the equation: 1
mU/ml of GPx activity = 1 nmol NADPH oxidized/min/
ml reaction mixture, using NADPH extinction coefficient
of 0.00622 AM/cm. Due to the use of organic hydroper-
oxide, this assay is specific for GPx activity and does not
interfere with peroxidase-like activity of catalase or mye-
loperoxidase [15].
2.6. Data analysis
Statistical analysis was done using STATISTICA 5.5
software (StatSoft, Tulsa, USA). Data are expressed as
median (range) or median (25–75 percentiles) where ap-
propriate. The Mann–Whitney U or Kruskal–Wallis tests
were applied to compare the data. Relationships between
variables were evaluated using the Spearman distribution-
free rank correlation test. A p value at 0.05 or less was
considered statistically significant.
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3.1. Sputum characteristics
Appropriate sputum samples were obtained from all
study individuals. Both spontaneous and induced CF spu-
tum samples were characterized by significantly higher cell
numbers compared to non-CF individuals and by over-
whelming neutrophil dominance in differential cell counts
(Table 2). There was no significant difference between CF
patients who provided spontaneous or induced sputum in
lung function, age and gender. In contrast, induced sputum
samples of healthy and asthmatic individuals contained
significantly higher percentages of pulmonary macrophages
(Table 2).
3.2. Sputum glutathione
Glutathione was detectable in all sputum samples. The
total glutathione levels in sputum samples of healthy indi-
viduals (median 2.3 AM (range 1.0–12.3)) and asthmatic
individuals (5.3 (1.3–19.2) AM) were within the same order
of magnitude ( p = 0.14; Fig. 1). The total glutathione con-
centrations in CF sputum samples were surprisingly high
(median value of 9.2 AM; p < 0.001 vs. healthy and asth-
matic individuals). There was no significant difference
between the sputum levels of total glutathione of CF
patients on NAC or ambroxol (13.0 vs. 11.0 AM;
p = 0.45). CF-induced sputum samples exhibited total glu-
tathione concentrations within the range of those found in
spontaneous sputum samples ( p>0.5; Fig. 1).
GSH, the form functional as an antioxidant, comprised
40.1% of total glutathione in induced sputum of healthyTable 2
Sputum parameters
Healthy (n= 14) Asthma (n= 12) CF (n= 42)
Volume (ml) 6.0
(2.5–13.0)
5.5
(2.5–15)
10.0
(0.5–25.0)
Weight (g) 5.4
(2.2–12.0)
5.6
(2.2–13.7)
10.0
(0.8–24.5)*
Total non-
squamous cell
no. ( 106)
2.2
(0.5–9.4)
3.6
(0.5–13.4)
17.3
(0.7–108.0)y
Non-squamous
cell viability (%)
74.0
(62.0–93.0)
89.5
(70.0–97.0)
90.0
(64.0–100)y
Macrophages (%) 68.0
(39.0–94.0)
71.0
(47.0–96.0)
2.0
(0.0–14.0)y
Neutrophils (%) 25.0
(4.0–56.0)
23.0
(2.0–35.0)
96.5
(83.0–100)y
Lymphocytes (%) 1.0
(0.0–3.0)
2.0
(1.0–5.0)
0.0
(0.0–4.0)y
Eosinophils (%) 0.0
(0.0–2.0)
0.0
(0.0–11.0)
0.5
(0.0–6.0)
Ciliated cells (%) 1.0
(0.0–7.0)
2.0
(0.0–9.0)
0.0
(0.0–1.0)y
Data are shown as median (range) values.
*p< 0.03 (Kruskal–Wallis test).
y p< 0.001 (Kruskal–Wallis test).individuals and 32.4% in samples from asthmatics (Fig. 1).
In marked contrast, GSH made up 90.7% of total glutathi-
one in CF sputum ( p< 0.001 vs. healthy and asthmatic
individuals).
In CF patients, GSH values were comparable between
male and female patients ( p = 0.52). Further, in CF patients,
GSH did not correlate with pulmonary function parameters
(Spearman’s r < 0.18 for GSH vs. FEV1 or FVC).
3.3. Glutathione peroxidase in CF sputum
Activity of glutathione peroxidase was detectable in all
tested CF sputum samples (median activity of 47.5 mU/g
sputum (range 13.7–128.2)). Acid-precipitation of proteins
reduced the reaction by nearly 100%, suggesting that
scavenging properties of CF sputum toward organic per-
oxides are represented by a protein.4. Discussion
Major components of the glutathione redox system (GSH
and GSSG and glutathione peroxidase) were quantified in
spontaneous and induced sputum of CF patients. To allow
for such analysis, DTT, a reagent traditionally used to
liquidify sputum, was skipped from the sputum processing
procedure as it was previously demonstrated to interfere
with enzymatic kinetic GSH assay. Instead, the authors used
PBS to obtain sputum supernatant for GSH analysis.
Differential cell counts from both CF spontaneous and
induced sputum demonstrate a clear neutrophil-dominated
inflammation and these findings are well in agreement with
the previous findings in CF sputum and BAL [16–21].
Although the majority of adult CF patients can easily
expectorate sputum, sputum induction offers some advan-
tages. First, sputum induction allows to sample airway
secretions even in patients with milder disease who other-
wise may experience problems providing a valid sputum
sample. Second, in the authors’ experience, CF airway
secretions obtained by sputum induction are somewhat
easier to process and contain more viable cells [21]. Yet,
sputum induction requires specific equipment (e.g. ultrason-
ic nebulizer, etc.) and trained personnel both of which may
currently not be available in all CF outpatient clinics.
Therefore, the present study was designed to study a
feasibility of GSH evaluation in both spontaneous and
induced CF sputum. The authors did not attempt to perform
a direct comparison between CF sputum samples obtained
in both ways which is certainly an interesting research
avenue to explore. However, the data from this study
indicate that both sputum samples appear to be comparable
in their GSH contents.
In contrast to CF patients, healthy and asthmatic indi-
viduals do not normally produce sputum spontaneously.
Therefore, sputum induction was used to obtain airway
secretions in these control subjects.
Fig. 1. Glutathione levels in sputum samples of healthy (H), asthmatic (A), and CF individuals. In healthy and asthmatic individuals, sputum was induced by
inhalation of 3% NaCl. CF patients provided spontaneous (CF spont.) and samples induced by 3% NaCl (CF ind.). The main graphic represents data of sputum
total glutathione shown as individual values, median, and 25–75 percentiles. The smaller graphic shows median (25–75 percentiles) levels of sputum GSH
expressed as percentage of total glutathione. Both total glutathione and GSH levels in CF sputum samples are significantly ( p< 0.001) higher than the levels in
non-CF samples.
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crepancy between GSH levels in sputum and BAL in CF. In
previous studies [8], GSH levels in BAL of CF patients
were significantly lower than those of non-CF controls.
Exactly the opposite was found in CF sputum. CF sputum
GSH levels were surprisingly high and in fact much higher
than those of healthy and asthmatic individuals. This dis-
crepancy can be explained in several ways. First, sputum
certainly is more representative for upper airways, while
BAL is sampling lower airways. Therefore, the difference
between this and previous findings on CF airway GSH may
be due to the studying different regions of respiratory tract.
Second, although both sputum and BAL analysis provide
insights on levels of substances in airway ELF, the lack of a
reliable marker of ELF dilution makes it difficult to compare
data obtained in different studies and from different indi-
viduals. This also limits the direct comparison between ELF
in healthy individuals and patients with lung diseases. Third,
it is possible that ‘‘higher’’ sputum GSH levels in CF may
simply represent a more efficient sampling of airway secre-
tions in these patients compared to non-CF controls. In this
case, the unavoidable dilution of upper airway secretions
during sputum induction in non-CF individuals would
balance out initially comparable or even higher, than in
CF airways, GSH levels. Fourth, CF airway secretions
contain high levels of apoptotic inflammatory cells, such
as neutrophils. These cells are known to release GSH upon
apoptosis [22,23]. GSH occurs intracellularly in millimolar
concentrations [2] and its release from apoptotic cells could
elevate extracellular GSH levels in airways. Neutrophils are
also known to contain high concentrations of catalase which
was demonstrated as abundant in CF sputum by previousstudy [24] and glutathione peroxidase which was found in
CF sputum in the present study. The antioxidant release
may, therefore, represent a compensatory mechanism for the
extensive inflammation in CF airways. So, inflammatory
cells of CF sputum may be considered an important source
of GSH.
Another surprising finding of the present study was the
fact that more than 90% of the total glutathione in CF
sputum was in reduced form (i.e. as GSH). This finding is in
a contrast with the data obtained in non-CF individuals
where more than 50% of total glutathione was oxidized. The
overabundance of other antioxidants in CF sputum, such as
catalase [24] and glutathione peroxidase (present study), as
well as the presence of high levels of protein thiols (the
authors’ unpublished observation) could explain the main-
tenance of glutathione in reduced form.
The CF group contained also some patients who were
using N-acetylcysteine at 600 mg daily. However, in the
authors’ opinion, it is unlikely that this fact would explain
high GSH levels in CF sputum. First, 600 mg/day is a dose
clearly lower those reported as being able to elevate GSH
levels in airway secretions (i.e. >1600 mg/day) [25]. Fur-
ther, GSH levels in sputum samples of patients on N-
acetylcysteine or ambroxol were found comparable in the
present study.
The present study could not answer, indeed, all the
questions on monitoring GSH in CF airway secretions. To
demonstrate that sputum GSH measurement is a reliable tool
to monitor antioxidant status in CF airways, several more
issues need to be addressed. The most important question
which still remains unclear is the reproducibility of GSH
measurement in terms of variability in stable patients. Also,
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status, it needs to be demonstrated that it responses to
antioxidant interventions, similar to what was demonstrated
with regard to eosinophils and cortisteroid treatment in
bronchial asthma. It would also be interesting to learn
how GSH sputum levels would be affected by the disease
state (i.e. remission vs. exacerbation). Future studies should
certainly answer these questions.
The present study did not reveal any significant relation-
ship between GSH and pulmonary function in CF. However,
future longitudinal observations shall be able to more
precisely evaluate the value of sputum GSH analysis as a
marker of activity of CF lung disease.
In conclusion, high concentrations of antioxidants were
found in both spontaneous and induced sputum samples of
stable adult CF patients. Sputum induction is a potentially
useful procedure to monitor airway antioxidant levels in CF
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